Leukaemia (lymphocytic) - fludarabine (TA119)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
Fludarabine given on its own is not recommended as an initial treatment for people with chronic lymphocytic leukaemia (CLL). Fludarabine is not licensed to be prescribed for CLL in combination with other chemotherapy medicines. This is because its 'marketing authorisation', which is normally needed before a drug can be prescribed, did not cover combination treatment. NICE was therefore unable to look at fludarabine in combination with other chemotherapy drugs for people with CLL. The process of giving a drug its marketing authorisation is not related to the NICE appraisal process and it is not carried out by NICE.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
This page was last updated: 14 January 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA119 Fludarabine ar gyfer lewcemia lymffosytig cronig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.